Isomorphic Labs, an AI drug-discovery company spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it looks to take drug candidates into clinical trials, TechCrunch reported on November 17. A Series C is a later fundraising round, usually after a startup has already shown more of its plan. Clinical trials are the tightly regulated human tests a potential medicine must pass before it can be widely prescribed.
TechCrunch reported that the round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and CapitalG (the story also refers to “Capita G”), Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund, also invested, according to the report.
The company builds an AI drug-design engine that uses simulation models to explore chemistry and help design drugs. TechCrunch said the work builds on DeepMind’s AlphaFold system, which predicts the three-dimensional shape of proteins from their genetic sequence. Isomorphic said, according to the report, that its program has yielded “positive preclinical results” in oncology and immunology — cancer and immune-system medicine — which means results from studies before human trials. The lab has also struck deals with large drugmakers, including Eli Lilly, Novartis, and Johnson & Johnson, TechCrunch reported.
The new funding comes after a $2.1 billion Series B round in May, the story said, and will be used to keep developing the drug-design engine and to move into more types of medicine. Isomorphic did not disclose its new valuation. TechCrunch noted that Bloomberg had reported earlier in the month that the lab was looking to raise money at a $50 billion valuation. That figure was a report about the company’s aims, not a confirmed price from Isomorphic itself.
The raise is the company’s first since its founder and chief executive, Demis Hassabis, left his role as head of DeepMind to focus on drug discovery, a move that also saw him become chairman at DeepMind, TechCrunch reported. Hassabis and then–DeepMind director John Jumper won the Nobel Prize in chemistry for their work on AlphaFold.
A $5 billion round is unusually large even in AI. It does not mean a new medicine is approved, only that investors are willing to fund the long, expensive path from computer models to possible human tests. This is a business story, not medical advice, and preclinical results are an early step, not a finished drug.